脂肪质量和肥胖相关蛋白质 (FTO) 抑制剂的专利化前景:2017年至今
Ze Dong1, Yue Huang1,2, Wenyang Xia2
1School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.
Expert opinion on therapeutic patents
|March 7, 2025
概括
针对脂肪质量和与肥胖相关的蛋白质 (FTO) 的小分子抑制剂在癌症治疗中表现有前途. 最近的专利揭示了新的化学实体,其中一个FTO抑制剂已进入急性髓性白血病的临床试验.
科学领域:
- 生物化学 生化学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 在瘤学瘤学.
背景情况:
- 脂肪质量和与肥胖相关的蛋白质 (FTO) 是一种通过m6A修饰调节基因表达的RNA脱甲基酶.
- 在各种癌症中,FTO经常过度表达,作为瘤原因子.
- 用小分子抑制剂向FTO是癌症治疗的有希望的治疗策略.
研究的目的:
- 审查关于作为FTO抑制剂开发的新型化学实体的专利文献.
- 突出FTO抑制在癌症治疗中的治疗潜力.
主要方法:
- 从2017年到现在,在Espacenet上搜索专利文献.
- 披露的化学实体作为FTO抑制剂的分析.
主要成果:
- 数十份声称使用新型FTO抑制剂的专利文件已被披露.
- FTO抑制剂CS1 (Bisantrene) 已进入急性髓性白血病 (AML) 的临床试验.
结论:
- 在表观遗传调节中FTO的作用使其成为癌症的重要治疗点.
- 在FTO抑制剂开发方面的进步,以CS1为例,正在刺激针对RNA表观遗传酶的第一类抗癌药物的研究.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Clinical Trials: Overview
2.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.6K
Enzyme Inhibition
77.7K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
77.7K
Drug Discovery: Overview
7.3K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.3K
Protein-protein Interfaces
12.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.4K


